suMMARY The acute pulmonary and systemic haemodynamic response to low (0. 15 mg/kg) and high (0.30 mg/kg) doses of intravenous hydralazine was evaluated in 26 consecutive patients with severe pulmonary hypertension due to cor pulmonale (nine patients), primary pulmonary hypertension (11 patients), or pulmonary embolism (six patients). Hydralazine did not cause a significant change in pulmonary arterial resistance or pressure in any group but produced a significant reduction in systemic resistance, which correlated with plasma concentration, and a significant increase in pulmonary blood flow index in all groups. Ten patients who experienced a reduction in pulmonary arterial resistance of at least 5 U.m2 after administration of hydralazine had higher initial values for pulmonary arterial resistance and systemic resistance and a lower pulmonary blood flow index than those who did not respond. Maintenance oral hydralazine treatment during nine to 36 months of follow up did not seem to affect symptoms or mortality. These results indicate that hydralazine has limited value in acutely reducing pulmonary arterial pressure or affecting clinical outcome in patients with pulmonary hypertension. 
The treatment of symptomatic pulmonary hypertension continues to be a perplexing problem, and results have generally been disappointing for both primary and secondary forms. Studies of pharmacological agents, including isoproterenol,1-4 tolazoline,47 phentolamine,8 verapamil,9 nifedipine,t0 diazoxide,11-13 isosorbide dinitrate,14 and prostaglandins, 15 have usually concerned oily a few patients and the results have been promising but equivocal. Recent reports1 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] have suggested that the vasodilator hydralazine substantially reduces pulmonary resistance in some patients with primary pulmonary hypertension or cor pulmonale, perhaps by a prostaglandin mediated mechanism.19 A thorough study of pulmonary hypertension and the results of drug intervention is difficult. The with pulmonary embolism; in addition, ventilation perfusion lung scanning was performed in two, pulmonary angiography in two, and lung biopsy in one. All patients underwent catheterisation of the right side of the heart. An arterial cannula was used for blood sampling and continuous monitoring of systemic pressure. The following measurements were obtained with the patients supine and resting: pulmonary and systemic arterial pressure, oxygen saturations, pulmonary wedge pressure (10 patients), left atrial pressure (eight patients), left ventricular pressure (three patients), and pH and arterial blood gas measurements. At each stage of the study cardiac output was determined twice by using indocyanine green dye dilution techniques with injection into the pulmonary artery and sampling in the peripheral systemic artery. Six sets of measurements were obtained: (a) control values, (b) after 10 minutes of breathing 100% oxygen, (c) 10 minutes after resumption of breathing room air to confirm return to control values, (d) 10 minutes after intravenous administration of 0-15 mg/kg (low dose) hydralazine, (e) 10 minutes after intravenous administration of 0-30 mg/kg (high dose) hydralazine, and (f) 20 Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension 5-8±0.6t
Significantly different from control value (*p<0.01 and tp<0-05).
AVO2A, arteriovenous oxygen difference; H, hydrlazine; Pp, mean pulmonary arterial pressure; Ps, mean systemic arterial pressure; Qp, pulmonary blood flow index; Rp, total pulmonary vascular resistance (indexed); Rs, systemic arterial resistance (indexed).
after intravenous injection of low dose and high dose hydralazine are provided in Table 2 and depicted in Fig. 1 Hydralazine decreased pulmonary arterial resistance in all groups but the decrease was not significant (Fig. 1) . In contrast, systemic arterial resistance was significantly reduced (groups 1 and 2 p<001; group 3 p<0-05). Cardiac index increased significantly in patients with parenchymal lung disease (p<001), primary pulmonary hypertension (p<0. 01), and pulmonary embolism (p<005). No significant change in mean pulmonary arterial pressure was noted in any group.
Immediate adverse effects of hydralazine were transient and relatively mild. Five patients experienced asymptomatic hypotension (systolic blood pressure of less than 85 mm Hg) during or shortly after catheterisation, and this complication was managed with administration of fluids. Nausea and vomiting developed in two patients, and one patient had a prolonged (two hour) sinus tachycardia (heart rate of more than 120 beats/min).
RESPONDERS V NON-RESPONDERS
To determine whether differences in baseline characteristics might predict the acute haemodynamic response to hydralazine, patients were classified as responders or non-responders. Patients were characterised as responders if indexed total pulmonary arterial resistance decreased by more than 5
Wood units (U.m2) after administration of either low dose or high dose hydralazine or at the time of late plateau measurements. Non-responders had decreases of less than 5 U*m2 or increases in pulmonary arterial resistance. Table 3 summarises the characteristics of each group. Differences among subgroups were not significant, though patients with primary pulmonary hypertension seemed least likely to respond. A higher proportion of females (50%) than males (25%) were responders. The mean age was somewhat higher for the responders than for the non-responders. Table 4 shows the observed haemodynamic responses after the intravenous administration of hydralazine. Control pulmonary arterial resistance was significantly higher in responders than in nonresponders (p<0-025). The absolute decrease in mean pulmonary arterial resistance was greater for the responders (as expected by definition), and the percentage decrease in resistance among the responders was also significantly greater than for the nonresponders (-312 -+ 2.8% v -8*5 + 3-1%). Responders also had a higher baseline systemic arterial resistance (p<O-O1) and a lower pulmonary blood flow index (p<0-005) than non-responders. Although systemic arterial resistance decreased and pulmonary blood flow index increased significantly after administration of hydralazine in both groups (p<0001 in all cases), the magnitude of change was greater in the responders ( but had a subsequent increase after receiving the higher dose. Four non-responders had a slight additional decrease in pulmonary arterial resistance (less than 2 U.m2) during the late plateau phase, but in no case did a non-responder become a responder. Plasma hydralazine concentration at the time of lowest pulmonary arterial resistance was 0*94+0*29 ,ug/ml for responders (five patients) and 0*64±+0-11 ,jg/ml for non-responders (10 patients); the difference was not significant. Despite the higher concentration in responders, no significant correlation was noted between the peak decrease in pulmonary arterial resistance and the concomitant hydralazine Haemodynamic response to intravenous hydralazine in patients with pulmonaty hypertension NS, not significant. For other abbreviations see Table 2 .
concentration. This finding was in contrast to a significant (p<0.05) correlation between hydralazine concentration and reduction in systemic arterial resistance (Fig. 2) .
FOLLOW UP
Follow up data were obtained for 24 patients and are summarised in Table 5 . Two patients (one responder and one non-responder) were lost to follow up. Nine patients were responders and 15 were nonresponders; the-mean duration of follow up was 16 months and 15 months after catheterisation, respectively. Of the two living responders, one had taken hydralazine orally (200 mg daily) since his admission to hospital, and he noted alleviation of his dyspnoea. The living responder who had not taken hydralazine also felt better. Of the eight living non-responders, four were taking hydralazine orally (60 to 200 mg daily) and two of these four had subjective improvement. tTwo responders and one non-responder died in the hospital and thus had no opportunity to receive maintenance oral hydralazine.
orally on a chronic basis after the haemodynamic study.
These conclusions differ from those of previous studies. Rubin and Peter '6 17 reported that four patients with primary pulmonary hypertension and 12 +20-c~1 0. 
